Randomized controlled clinical trial of zinc supplementation in HIV-1 infected adults
Baum MK, Lai S, Sales S, Page JB, Campa A
Published in Clinical Infectious Diseases
Methodology
Double-blind placebo-controlled trial of zinc 12-15 mg/day in HIV-1 infected adults
Key Findings
Zinc supplementation reduced the likelihood of immunological failure fourfold, but HIV viral load did not differ significantly between zinc and placebo groups.
Conclusions
Zinc preserved CD4 counts and reduced diarrhoea without measurably lowering HIV viral load.
Limitations
Single-site drug-using cohort; adherence self-reported; viral load a secondary endpoint.
Supplements Studied
Zinc preserved CD4 counts but did not significantly lower HIV viral load.
Outcomes Measured
HIV viral load did not differ significantly between zinc and placebo groups.
Study Details
Access Study
Disclosures
Funding
NIH / NIDA
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.